Kit For The Preparation Of Technetium Tc99m Sestamibi Injection, Powder, Lyophilized, For Solution
NDC Package 11994-003-20

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Kit For The Preparation Of Technetium Tc99m Sestamibi (tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate) injection is none known. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Lantheus Medical Imaging, Inc., this product is identified by NDC 11994-003 and is authorized under FDA application NDA019785.

Identification & Billing

NDC Package Code
11994-003-20
Package Description
20 VIAL in 1 BOX / 5 mL in 1 VIAL
Product Code
11-Digit Billing Format
11994000320
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA

Clinical Specifications

Proprietary Name
Kit For The Preparation Of Technetium Tc99m Sestamibi
Non-Proprietary Name
Tetrakis(2-methoxyisobutylisocyanide)copper(i) Tetrafluoroborate
Substance Name
Tetrakis(2-methoxyisobutylisocyanide)copper(i) Tetrafluoroborate
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Usage Information
None known.

Regulatory & Marketing

Labeler Name
Lantheus Medical Imaging, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA019785
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-20-1990
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 11994-003-20 identifies a specific commercial package of 20 vial in 1 box / 5 ml in 1 vial of Kit For The Preparation Of Technetium Tc99m Sestamibi, a human prescription drug labeled by Lantheus Medical Imaging, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lantheus Medical Imaging, Inc. on December 20, 1990. The current certification is valid through December 31, 2026.

How is this Lantheus Medical Imaging, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 11994000320. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
11994-003-20
11-Digit CMS (5-4-2)
11994-0003-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.